A Network Pharmacology Approach to Reveal the Underlying Mechanisms of on the Treatment of Hepatocellular Carcinoma

Overview

Journal Evid Based Complement Alternat Med

Specialty Rehabilitation Medicine

Date 2021 Mar 10

PMID 33688369

Citations 8

Authors

Shuqiao Zhang

Zhuomao Mo

Shijun Zhang

Xinyu Li

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the potential active ingredients and underlying mechanisms of (AA) on the treatment of hepatocellular carcinoma (HCC) based on network pharmacology.

Methods: In the present study, we used a network pharmacological method to predict its underlying complex mechanism of treating HCC. First, we obtained relative compounds of AA based on the traditional Chinese medicine systems pharmacology (TCMSP) database and collected potential targets of these compounds by target fishing. Then, we built HCC-related targets target by the oncogenomic database of hepatocellular carcinoma (OncoDB.HCC) and biopharmacological network (PharmDB-K) database. Based on the matching results between AA potential targets and HCC targets, we built a protein-protein interaction (PPI) network to analyze the interactions among these targets and screen the hub targets by topology. Furthermore, the function annotation and signaling pathways of key targets were performed by Gene Oncology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis using DAVID tools. Finally, the binding capacity between active ingredients and key targets was validated by molecular docking.

Results: A total of 19 main active ingredients of AA were screened as target prediction; then, 25 HCC-related common targets were seeked out via multiple HCC databases. The areas of nodes and corresponding degree values of EGFR, ESR1, CCND1, MYC, EGF, and PTGS2 were larger and could be easily found in the PPI network. Furthermore, GO and KEGG enrichment analysis showed that these key targets were significantly involved in multiple biological processes and pathways which participated in tumor cell proliferation, apoptosis, angiogenesis, tumor invasion, and metastasis to accomplish the anti-HCC activity. The molecular docking analysis showed that quercetin could stably bind to the active pocket of EGFR protein 4RJ5 via LibDock.

Conclusion: The anticancer effects of AA on HCC were predicted to be associated with regulating tumor cell proliferation, apoptosis, angiogenesis, tumor invasion, and metastasis via various pathways such as the EGFR signaling pathway, ESR1 signaling pathway, and CCND1 signaling pathway. It is suggested that AA might be developed as a broad-spectrum antitumor drug based on its characteristics of multicomponent, multipath, and multitarget.

Citing Articles

Potential Antiproliferative and Antimetastatic Effects of : An In Vitro Study Focused on Hepatocarcinoma Cells.

Pace L, Ragusa F, Lizzi L, Armillotta M, Massimi M Biology (Basel). 2025; 13(12.

PMID: 39765651 PMC: 11727042. DOI: 10.3390/biology13120985.

Green synthesis of Brassica carinata microgreen silver nanoparticles, characterization, safety assessment, and antimicrobial activities.

Somda D, Bargul J, Wesonga J, Wachira S Sci Rep. 2024; 14(1):29273.

PMID: 39587236 PMC: 11589588. DOI: 10.1038/s41598-024-80528-6.

Phytochemical analysis, and study of antiproliferative activity of ethyl acetate fraction of (Hochst. ex Oliv. & Hiern) C. Jeffrey against human cervical cancer cell line.

Lagu I, Nyamai D, Njeru S Front Pharmacol. 2024; 15:1399885.

PMID: 39005932 PMC: 11239972. DOI: 10.3389/fphar.2024.1399885.

Computational biology and in vitro studies for anticipating cancer-related molecular targets of sweet wormwood (Artemisia annua).

Dawood H, Celik I, Ibrahim R BMC Complement Med Ther. 2023; 23(1):312.

PMID: 37684586 PMC: 10492370. DOI: 10.1186/s12906-023-04135-0.

Integrating Network Pharmacology and Bioinformatics to Explore the Effects of Dangshen () Against Hepatocellular Carcinoma: Validation Based on the Active Compound Luteolin.

Yu Y, Ding S, Xu X, Yan D, Fan Y, Ruan B Drug Des Devel Ther. 2023; 17:659-673.

PMID: 36883114 PMC: 9985903. DOI: 10.2147/DDDT.S386941.

References

Zhang Y, Liang Y, He C . Anticancer activities and mechanisms of heat-clearing and detoxicating traditional Chinese herbal medicine. Chin Med. 2017; 12:20. PMC: 5506596. DOI: 10.1186/s13020-017-0140-2. View

Efferth T . Cancer combination therapies with artemisinin-type drugs. Biochem Pharmacol. 2017; 139:56-70. DOI: 10.1016/j.bcp.2017.03.019. View

Vandewynckel Y, Laukens D, Geerts A, Vanhove C, Descamps B, Colle I . Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial agent. Eur J Gastroenterol Hepatol. 2014; 26(8):861-70. DOI: 10.1097/MEG.0000000000000066. View

Qu D, Cui F, Lu D, Yang Y, Xu Y . DEP domain containing 1 predicts prognosis of hepatocellular carcinoma patients and regulates tumor proliferation and metastasis. Cancer Sci. 2018; 110(1):157-165. PMC: 6317931. DOI: 10.1111/cas.13867. View

von Hagens C, Walter-Sack I, Goeckenjan M, Osburg J, Storch-Hagenlocher B, Sertel S . Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2). Breast Cancer Res Treat. 2017; 164(2):359-369. DOI: 10.1007/s10549-017-4261-1. View

Wu H, Pan L, Gao C, Xu H, Li Y, Zhang L . Quercetin Inhibits the Proliferation of Glycolysis-Addicted HCC Cells by Reducing Hexokinase 2 and Akt-mTOR Pathway. Molecules. 2019; 24(10). PMC: 6572074. DOI: 10.3390/molecules24101993. View

Feng X, Rong L, Wang R, Zheng X, Zhang L, Zhang L . Luteolin and sorafenib combination kills human hepatocellular carcinoma cells through apoptosis potentiation and JNK activation. Oncol Lett. 2018; 16(1):648-653. PMC: 6006184. DOI: 10.3892/ol.2018.8640. View

Huang P, Xu X, Wang L, Zhu B, Wang X, Xia J . The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment. J Cell Mol Med. 2013; 18(2):218-30. PMC: 3930409. DOI: 10.1111/jcmm.12153. View

Van Der Kooy F, Sullivan S . The complexity of medicinal plants: the traditional Artemisia annua formulation, current status and future perspectives. J Ethnopharmacol. 2013; 150(1):1-13. DOI: 10.1016/j.jep.2013.08.021. View

10.

Wang L, Yao J, Shi X, Hu L, Li Z, Song T . MicroRNA-302b suppresses cell proliferation by targeting EGFR in human hepatocellular carcinoma SMMC-7721 cells. BMC Cancer. 2013; 13:448. PMC: 3850949. DOI: 10.1186/1471-2407-13-448. View

11.

Lanaya H, Natarajan A, Komposch K, Li L, Amberg N, Chen L . EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. Nat Cell Biol. 2014; 16(10):972-7. PMC: 4183558. DOI: 10.1038/ncb3031. View

12.

Efferth T . Cancer combination therapy of the sesquiterpenoid artesunate and the selective EGFR-tyrosine kinase inhibitor erlotinib. Phytomedicine. 2017; 37:58-61. DOI: 10.1016/j.phymed.2017.11.003. View

13.

Huang Y, Hwang J, Lee P, Ke F, Huang J, Huang C . Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor. Br J Pharmacol. 1999; 128(5):999-1010. PMC: 1571723. DOI: 10.1038/sj.bjp.0702879. View

14.

Fujiwara N, Friedman S, Goossens N, Hoshida Y . Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol. 2017; 68(3):526-549. PMC: 5818315. DOI: 10.1016/j.jhep.2017.09.016. View

15.

Liao X, Tao L, Liu J, Gu Y, Xie J, Chen Y . Matrine combined with cisplatin synergistically inhibited urothelial bladder cancer cells via down-regulating VEGF/PI3K/Akt signaling pathway. Cancer Cell Int. 2018; 17:124. PMC: 5745706. DOI: 10.1186/s12935-017-0495-6. View

16.

Wang D, Meng G, Zheng M, Zhang Y, Chen A, Wu J . The Glutaminase-1 Inhibitor 968 Enhances Dihydroartemisinin-Mediated Antitumor Efficacy in Hepatocellular Carcinoma Cells. PLoS One. 2016; 11(11):e0166423. PMC: 5105986. DOI: 10.1371/journal.pone.0166423. View

17.

Zhang G, Li Q, Chen Q, Su S . Network pharmacology: a new approach for chinese herbal medicine research. Evid Based Complement Alternat Med. 2013; 2013:621423. PMC: 3671675. DOI: 10.1155/2013/621423. View

18.

Efferth T . From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy. Semin Cancer Biol. 2017; 46:65-83. DOI: 10.1016/j.semcancer.2017.02.009. View

19.

Fu Y, Liu S, Zeng S, Shen H . From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. J Exp Clin Cancer Res. 2019; 38(1):396. PMC: 6734524. DOI: 10.1186/s13046-019-1396-4. View

20.

Saeed M, Breuer E, Hegazy M, Efferth T . Retrospective study of small pet tumors treated with Artemisia annua and iron. Int J Oncol. 2019; 56(1):123-138. PMC: 6910181. DOI: 10.3892/ijo.2019.4921. View